Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,980,601 shares of the company's stock after selling 786,127 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 2.30% of Recursion Pharmaceuticals worth $60,709,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 16.4% in the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company's stock valued at $215,949,000 after purchasing an additional 4,626,268 shares during the period. State Street Corp increased its holdings in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock worth $35,803,000 after buying an additional 656,003 shares during the last quarter. Institute for Wealth Management LLC. purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $3,928,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Recursion Pharmaceuticals by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company's stock valued at $12,789,000 after acquiring an additional 288,926 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Up 1.9 %

Recursion Pharmaceuticals stock traded up $0.16 during trading on Thursday, hitting $8.50. The company had a trading volume of 28,634,961 shares, compared to its average volume of 20,561,834. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $15.74. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company's 50 day simple moving average is $7.22 and its 200-day simple moving average is $6.90. The stock has a market cap of $3.32 billion, a price-to-earnings ratio of -5.56 and a beta of 0.86.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Needham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.